Buy Stocks Easy | About Us
January 29, 2022
Buy Stocks Easy | Online Stocks

AKTX


Buy Akari Therapeutics Plc Stock (symbol: AKTX) Easy Online

Company Name: Akari Therapeutics Plc

Symbol: AKTX

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2015

AKTX Current Share Price

Today's AKTX ( Akari Therapeutics Plc ) opening price: $1.7400

Yesterday's AKTX ( Akari Therapeutics Plc ) closing price: $1.7400

Akari Therapeutics Plc Stock ( symbol: AKTX ) Price Chart since IPO (2015):

12 Months Akari Therapeutics Plc Stock ( symbol: AKTX ) Price Chart

Popular Questions about Akari Therapeutics Plc Public Stock ( AKTX )

A: Akari Therapeutics Plc stock symbol (also called stock or share ticker) is AKTX

A: Akari Therapeutics Plc IPO (Initial Public Offering) took place on 2015

A: Akari Therapeutics Plc's stock (AKTX symbol) price at ther IPO (initial Public Offering) was $1.7400

Q: Is AKTX stock worth buying at the moment?

A: The AKTX stock performance since 2019 are rather disappointing. If you had bought 1 share of Akari Therapeutics Plc stock (symbol: AKTX) at the beginning of 2019, at the opening share price of $2.0098, you would be left with exactly $1.7400 - which means a waste of your money and time. - SHOW ONLY IF equal or loose.

Buy Akari Therapeutics Plc Stock Easy Online

Akari Therapeutics Plc Stock Ticker Price Chart since IPO:





Akari Therapeutics Plc Stock Price Yesterday



 


Akari Therapeutics Plc Stock Price – Last Week




 


Akari Therapeutics Plc Stock Price – Last Month




 


Akari Therapeutics Plc Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/14/1929177/0/en/Akari-Therapeutics-Announces-New-Data-from-Atopic-Keratoconjunctivitis-AKC-Patients-Supporting-the-Potentially-Beneficial-Role-of-Nomacopan-as-an-Inhibitor-of-both-C5-and-LTB4-in-t.html
                            

                                
Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial

                                
                                
NEW YORK and LONDON, Oct.  14, 2019  (GLOBE NEWSWIRE) -- Akari Ther...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/10/1928049/0/en/Akari-Therapeutics-Announces-Positive-Phase-II-Clinical-Data-in-Orphan-Blistering-Skin-Disease-Bullous-Pemphigoid-at-the-28th-EADV-Congress.html
                            

                                
Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress

                                
                                
NEW YORK and LONDON, Oct.  10, 2019  (GLOBE NEWSWIRE) -- Akari Ther...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/18/1917294/0/en/Akari-Therapeutics-to-Participate-in-Ladenburg-Thalmann-Healthcare-Conference.html
                            

                                
Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference

                                
                                
NEW YORK and LONDON, Sept.  18, 2019  (GLOBE NEWSWIRE) -- Akari The...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/13/1915375/0/en/Akari-Therapeutics-Nomacopan-Granted-U-S-Orphan-Drug-Designation-for-Bullous-Pemphigoid.html
                            

                                
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid

                                
                                
NEW YORK and LONDON, Sept.  13, 2019  (GLOBE NEWSWIRE) -- Akari The...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/03/1909853/0/en/Akari-Therapeutics-to-Participate-in-Citi-and-H-C-Wainwright-Conferences-in-Early-September.html
                            

                                
Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September

                                
                                
NEW YORK and LONDON, Sept.  03, 2019  (GLOBE NEWSWIRE) -- Akari The...


                            

                        
                    

                


                            

                    


                        
                            https://www.marketwatch.com/story/akari-therapeutics-shares-soar-13-premarket-after-fda-grants-orphan-drug-designation-to-nomacopan-2019-08-30
                            

                                
Akari Therapeutics shares soar 13% premarket after FDA grants Orphan Drug designation to nomacopan

                                
                                
Akari Therapeutics PLC shares AKTX, +12.21% soared 13% in premarket...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/08/30/1908980/0/en/Akari-Therapeutics-Nomacopan-Granted-U-S-Orphan-Drug-Designation-for-Hematopoietic-Stem-Cell-Transplantation-Associated-Thrombotic-Microangiopathy-HSCT-TMA.html
                            

                                
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA)

                                
                                
NEW YORK and LONDON, Aug.  30, 2019  (GLOBE NEWSWIRE) -- Akari Ther...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/23/1964096/0/en/Akari-Therapeutics-Announces-Initiation-of-Pivotal-Phase-III-Trial-of-Nomacopan-in-Pediatric-Hematopoietic-Stem-Cell-Transplant-Related-Thrombotic-Microangiopathy-HSCT-TMA-Followin.html
                            

                                
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) Following the Opening of its IND

                                
                                
NEW YORK and LONDON, Dec.  23, 2019  (GLOBE NEWSWIRE) -- Akari Ther...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/14/1929177/0/en/Akari-Therapeutics-Announces-New-Data-from-Atopic-Keratoconjunctivitis-AKC-Patients-Supporting-the-Potentially-Beneficial-Role-of-Nomacopan-as-an-Inhibitor-of-both-C5-and-LTB4-in-t.html
                            

                                
Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial

                                
                                
NEW YORK and LONDON, Oct.  14, 2019  (GLOBE NEWSWIRE) -- Akari Ther...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/10/1928049/0/en/Akari-Therapeutics-Announces-Positive-Phase-II-Clinical-Data-in-Orphan-Blistering-Skin-Disease-Bullous-Pemphigoid-at-the-28th-EADV-Congress.html
                            

                                
Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress

                                
                                
NEW YORK and LONDON, Oct.  10, 2019  (GLOBE NEWSWIRE) -- Akari Ther...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/18/1917294/0/en/Akari-Therapeutics-to-Participate-in-Ladenburg-Thalmann-Healthcare-Conference.html
                            

                                
Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference

                                
                                
NEW YORK and LONDON, Sept.  18, 2019  (GLOBE NEWSWIRE) -- Akari The...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/13/1915375/0/en/Akari-Therapeutics-Nomacopan-Granted-U-S-Orphan-Drug-Designation-for-Bullous-Pemphigoid.html
                            

                                
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid

                                
                                
NEW YORK and LONDON, Sept.  13, 2019  (GLOBE NEWSWIRE) -- Akari The...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/03/1909853/0/en/Akari-Therapeutics-to-Participate-in-Citi-and-H-C-Wainwright-Conferences-in-Early-September.html
                            

                                
Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September

                                
                                
NEW YORK and LONDON, Sept.  03, 2019  (GLOBE NEWSWIRE) -- Akari The...


                            

                        
                    

                


                            

                    


                        
                            https://www.marketwatch.com/story/akari-therapeutics-shares-soar-13-premarket-after-fda-grants-orphan-drug-designation-to-nomacopan-2019-08-30
                            

                                
Akari Therapeutics shares soar 13% premarket after FDA grants Orphan Drug designation to nomacopan

                                
                                
Akari Therapeutics PLC shares AKTX, +12.21% soared 13% in premarket...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.